Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) EBITDA Margin (2022 - 2025)

Bioregenx (BRGX) has 4 years of EBITDA Margin data on record, last reported at 14.44% in Q3 2025.

  • For Q3 2025, EBITDA Margin rose 5223.0% year-over-year to 14.44%; the TTM value through Sep 2025 reached 980.86%, down 68140.0%, while the annual FY2024 figure was 985.04%, 88006.0% down from the prior year.
  • EBITDA Margin reached 14.44% in Q3 2025 per BRGX's latest filing, up from 41.6% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 161.38% in Q3 2022 and bottomed at 68266.53% in Q3 2023.
  • Average EBITDA Margin over 4 years is 4973.73%, with a median of 66.68% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: crashed -6842792bps in 2023, then surged 6819985bps in 2024.
  • A 4-year view of EBITDA Margin shows it stood at 62.09% in 2022, then plummeted by -614bps to 443.16% in 2023, then plummeted by -801bps to 3995.01% in 2024, then soared by 100bps to 14.44% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 14.44% in Q3 2025, 41.6% in Q2 2025, and 52.2% in Q1 2025.